Top

Published in:

Open Access 01-12-2012 | Meeting abstract

Recent advances in myelodysplasia: update from 2011 ASH annual meeting

Author: Delong Liu

Published in: Journal of Hematology & Oncology | Special Issue 1/2012

Excerpt

Significant progresses have been made in genetic research in MDS. Through RNA interference technology, knock-down of RPS14 recapitulated the pathological process of decreased erythropoiesis [1]. Transgenic expression of RPS14 in 5q- MDS cells rescued the phenotype of insufficient erythropoiesis. This strongly suggests that haploinsufficiency of RPS14 is one of the molecular mechanisms in the pathogenesis of 5q- MDS. SF3B1 is a core component of RNA splicesome and involved in the regulation of the mitochondrial pathway. In a study of 533 patients (pts) with MDS, 150 (28.1%) was found to have SF3B1 gene mutation, which has a positive predictive value of 97.7% for RARS and correlates well with better overall survival (OS) and lower risk for AML transformation [2, 3]. …

Ebert BL, Pretz J, Bosco J, Chang CY, Tamayo P, Galili N, Raza A, Root DE, Attar E, Ellis SR: Identification of RPS14 as a 5q- syndrome gene by RNA interference screen. Nature. 2008, 451 (7176): 335-339. 10.1038/nature06494.PubMedCentralCrossRefPubMed

Malcovati L, Papaemmanuil E, Hellstrom-Lindberg E, Boultwood J, Bowen D, Vyas P, Pascutto C, Porta MGD, Pellagatti A, Groves MJ: Somatic Mutation of SF3B1, a Gene Encoding a Core Component of RNA Splicing Machinery, in Myelodysplasia with Ring Sideroblasts. ASH Annual Meeting Abstracts. 2011, 118 (21): #3-

Malcovati L, Papaemmanuil E, Bowen DT, Boultwood J, Della Porta MG, Pascutto C, Travaglino E, Groves MJ, Godfrey AL, Ambaglio I: Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic/myeloproliferative neoplasms. Blood. 2011, 118 (24): 6239-6246. 10.1182/blood-2011-09-377275.PubMedCentralCrossRefPubMed

Graubert T, Walter MJ: Genetics of Myelodysplastic Syndromes: New Insights. ASH Education Program Book. 2011, 2011 (1): 543-549.

Traina F, Jankowska AM, Visconte V, Sugimoto Y, Szpurka H, Makishima H, Jerez A, O'Keefe CL, Sekeres MA, Advani AS: Impact of Molecular Mutations on Treatment Response to Hypomethylating Agents in MDS. ASH Annual Meeting Abstracts. 2011, 118 (21): #461-

Min Y-H, Yoon S, Hwang DY, Kim Y, Kim Y-K, Kim Y, Cho JY, Kim JS, Kim SJ, Cheong J-W: Circulating Exosomal MicroRNA-21 As a Potential Biomarker That May Predict Response to Azacitidine Treatment in Myelodysplastic Syndromes. ASH Annual Meeting Abstracts. 2011, 118 (21): #3804-

Sekeres MA, Komrokji RS, Lancet JE, Tiu RV, Advani AS, Afable M, Englehaupt R, Juersivich J, Cuthbertson D, Paleveda J: Final Results From the Phase 2 Continuation Study of the Lenalidomide and Azacitidine Combination in Patients with Higher-Risk Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts. 2011, 118 (21): #607-

Garcia-Manero G, Estey EH, Jabbour E, Borthakur G, Kadia T, Naqvi K, Levine RL, Estrov Z, Quintas-Cardama A, Konopleva M: Final Report of a Phase II Study of 5-Azacitidine and Vorinostat in Patients (pts) with Newly Diagnosed Myelodysplastic Syndrome (MDS) or Acute Myelogenous Leukemia (AML) Not Eligible for Clinical Trials Because Poor Performance and Presence of Other Comorbidities. ASH Annual Meeting Abstracts. 2011, 118 (21): #608-

Mistry B, Jones MM, Kubiak P, Garcia-Manero G, Litzow MR, Mesa RA, Rifkin R, Tarassoff P, Cortes JE: A Phase 1 Study to Assess the Absolute Bioavailability and Safety of An Oral Solution of Decitabine In Subjects with Myelodysplastic Syndromes (MDS). ASH Annual Meeting Abstracts. 2011, 118 (21): #3801-

10.

Suragani RN, Mulivor A, Pearsall RS, Kumar R: RAP-536 Promotes Terminal Erythroid Differentiation and Reduces Anemia in Myelodysplastic Syndromes. ASH Annual Meeting Abstracts. 2011, 118 (21): #610-

11.

Rhyasen G, Bolanos L, Fang J, Rigolino C, Cortelezzi A, Oliva EN, Cuzzola M, Starczynowski DT: Inhibition of IRAK1 As a Novel Therapeutic Strategy in Acute Myeloid Leukemia and Myelodysplastic Syndrome. ASH Annual Meeting Abstracts. 2011, 118 (21): #612-

12.

Cilloni D, Messa E, Biale L, Bonferroni M, Salvi F, Lunghi M, Allione B, Ferrero D, Freilone R, Levis A: High Rate of Erythroid Response During Iron Chelation Therapy in a Cohort of 105 Patients Affected by Hematologic Malignancies with Transfusional Iron Overload: An Italian Multicenter Retrospective Study. ASH Annual Meeting Abstracts. 2011, 118 (21): #611-

13.

Leitch HA, Chan C, Leger CS, Foltz LM, Ramadan KM, Vickars LM: Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis. ASH Annual Meeting Abstracts. 2011, 118 (21): #1732-

Title: Recent advances in myelodysplasia: update from 2011 ASH annual meeting
Author: Delong Liu
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue Special Issue 1/2012
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-5-S1-A4

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Special Issue 1/2012

T-cell immunodeficiency and reconstruction based on TCR rearrangement analysis in hematological malignancy: update from 2011 ASH annual meeting

Restoration of T cell tolerance in primary ITP

Targeting p53 by small molecule p53 activators in multiple myeloma

Overcoming Gleevec-resistance by blocking oncogene addiction in malignant hematologic cells

Epstein - Barr virus - associated Diseases in Allogeneic Hematopoietic Stem Cell Transplantation

Utilizing CD30 expression as a rational target for therapy of lymphoma

Keynote webinar | Spotlight on antibody–drug conjugates in cancer